Advertisement

Topics

Latest Prostate Cancer research and development NewsRSS

02:19 EDT 23rd August 2017 | BioPortfolio

What's Next for Bristol-Myers Squibb After Its Opdivo Setback?

Mixed results for a study with Opdivo in treating first-line kidney cancer give reasons for concern. But how worried should investors really be? reported its checkpoint inhibitor Imfinzi failed to improve progression-free survival in a late-stage study targeting lung cancer.

VolitionRX Ltd VNRX Product Pipeline Analysis, 2017 Update [Report Updated: 14072017] Prices from USD $750

SummaryVolitionRX Ltd VolitionRX is a medical equipment provider that develops diagnostics tests for cancer and other conditions. The company develops Nucleosomics, a platform technology used for measurement and identification of nucleosomes in the blood. It develops tools for the diagnosis of various conditions including colorectal cancer, prostate and lung cancers, and inflammatory and other dis...

GeneNews Ltd GEN Financial and Strategic SWOT Analysis Review [Report Updated: 07082017] Prices from USD $300

SummaryGeneNews Ltd GeneNews is a cancer solution providing company that offers molecular diagnostic products. The company develops and commercializes diagnostics and personalized medicine for cancer and other chronic diseases. Its Sentinel Principle is a novel approach to identifying biomarkers of body state using blood. GeneNews offers biomarkers for detect disease, stage diseases, monitor and p...

Xbrane Biopharma AB XBRANE Financial and Strategic SWOT Analysis Review [Report Updated: 07082017] Prices from USD $300

SummaryXbrane Biopharma AB Xbrane, formerly known as Xbrane Bioscience AB, is a biopharmaceutical company that develops and manufactures complex generics. The company's product portfolio includes biosimilars and generic drugs developed for people suffering from critical diseases. It combines its proprietary microsphere and protein production technology platforms to develop and produce generics dru...

Volition Signs Agreement with the Institute of Laboratory Medicine of the Technical University of Munich, Germany, to assist in securing large trials in a range of cancers

ISNES, Belgium, Aug. 22, 2017 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) today announced a three-year agreement to work with the renowned expert Professor Stefan Holdenrieder at the Institute of Laboratory Medicine of the German Heart Center at the Technical University of Munich, Germany. Volition's Chief Executive Officer, Cameron Reynolds, commented, "I am delighted w...

Using Molecular Tools to Guide Breast Cancer Treatment

This video examines the use of molecular diagnostics for guiding adjuvant endocrine therapy in patients with breast cancer.

Los Angeles Dodger Fans Help Strike Out Cancer During City of Hope’s Ninth Annual ThinkCure! Weekend

The Los Angeles community once again joins forces with City of Hope in the fight against cancer Nine cancer survivors and their physicians will take the field at Dodger Stadium on Saturday evening to kick off City of Hope’s ThinkCure! Weekend, an annual event that celebrates courageous cancer patients and survivors, and pays tribute to the hard-worki...

Novogen irons out Phase 2 plans for brain cancer candidate

Contract research organization Chiltern will help the company conduct a mid-stage study slated for the fourth quarter.

American Cancer Society Honors AmeriHealth Caritas Pennsylvania Medicaid Plans with Health Systems Excellence Award

AmeriHealth Caritas, a national leader in Medicaid managed care and other health care solutions for those most in need, announced today that two of its Medicaid health plans, AmeriHealth Caritas Pennsylvania and

Augmenix Ranked as One of America’s Fastest-Growing Private Companies for Second Year

Augmenix Maintains Spot in Top 10% of Metro-Boston Companies; Three-Year Growth over 2,000% Ranked Company Number 207 on Inc. Magazine’s Top 500 Augmenix, Inc., a medical technology company that develops, manufactures, and sells proprietary absorbable hydrogels that separate and protect organs at risk during radiotherapy, has again been named ...

Leading Illinois Cancer Program to Leverage Patient Engagement Technology to Improve Patient Outcomes

Northwest Oncology & Hematology Selects Navigating Cancer Platform to Streamline Workflow and Increase Efficiency Seattle, WA (PRWEB) August 22, 2017 Navigating Cancer and Northwest Oncology & Hematology (NWOH) are excited to announce their new partnership to implement Navigating Cancer’s technology platform. NWOH is one of Illinois’ most respected and experienced cancer centers and ...

August 2017 BSB Journal Club on Breast Cancer

Recently there has been a glut of encouraging new research published on the topic of breast cancer that is well…

Emerging Cancer Diagnostic Tests and Strategic Assessments of Leading Suppliers [Report Updated: 12072017] Prices from USD $3500

This 286page report presents comprehensive marketing and technological assessment, as well as medical rationale and diagnostic prospects, for the major categories of both circulating and cellular tests, such as Biochemical Markers, Oncogenes, Growth Factors, Hormones, Colony Stimulating Factors, Lymphokines, Immunohistochemical Stains and others.The report includes an overview of the clinical sign...

Cancer early warning system: Blood test looks for bits of DNA shed from tumors

Grid Therapeutics Signs Exclusive License Agreement to Develop a Novel Immuno-Oncology Antibody

Grid Therapeutics, LLC, an oncology-focused biotechnology company announced the execution of an exclusive license agreement with Duke University to develop the first human derived antibody as a targeted immunotherapy for cancer. Under the agreement, Grid has acquired the exclusive rights to all intellectual property, including

US patent for Jamaican anti-cancer weed

Jamaican researchers have been granted a US patent for the discovery of anti-cancer activity in guinea hen weed (petiveria alliacea).

New Data on High Dose Vitamin C Therapy and Prostate Cancer

WICHITA, Kan., Aug. 22, 2017 /PRNewswire-USNewswire/ -- Riordan Clinic scientist Nina Mikirova, PhD, and medical doctor Ronald Hunninghake, MD, have recently published a study in the Journal of Functional Food for Health and Disease entitled:  "Changes in the rate of PSA progression and the level of alkaline phosphatase during high dose vitamin C treatment of patients with prostate c...

Hyundai Hope On Wheels Presents Vannie E. Cook Jr. Children's with $50,000 Hyundai Impact Award to Support Pediatric Cancer Care

MCALLEN, Texas, Aug. 22, 2017 /PRNewswire/ -- Hyundai Hope On Wheels® will today present Vannie E. Cook Jr. Children's Cancer & Hematology Clinic with a $50,000 Hyundai Impact Award. Vannie E. Cook Jr. Children's is one of 25 recipients of this year's award, which is given to pediatric oncology departments at select children's hospitals nationwide. Vannie E. Cook Jr. Children's plans to ...

The Gastroesophageal Cancer Market is Expected to Grow Sevenfold Over the Next Ten Years Capturing $13 Billion in 2026

BURLINGTON, Mass., Aug. 22, 2017 /PRNewswire/ -- Decision Resources Group finds that the gastroesophageal cancer market will grow significantly from almost $2 billion in 2016 to $13 billion in 2026, making it one of the fastest growing oncology indications. Fueling this robust growth will be the approval of multiple novel premium-priced biologics, namely PD-1/PD-L1 inhibitors. ...

Drs. Mehmet Altan, Valsamo Anagnostou, and Zofia Piotrowska Receive 2017 LUNGevity Career Development Awards

WASHINGTON, Aug. 22, 2017 /PRNewswire-USNewswire/ -- LUNGevity Foundation today announced the recipients of its 2017 Career Development Awards (CDA) for lung cancer research. These coveted awards fund critical lung cancer research projects and offer the recipients world-class mentorship by LUNGevity's prestigious Scientific Advisory Board. "LUNGevity created the CDAs to identify outstand...

Prostate Cancer Patients Improve Bone Health with Osteoporosis Drugs by Dr David Samadi

Dr David Samadi, Chairman of Urology at Lenox Hill Hospital, provides his expert opinion on a new study finding men with non-metastatic prostate cancer who are receiving androgen deprivation therapy have improved bone mineral density using osteoporosis medications. (PRWEB) August 22, 2017 It is well known that men who receive androgen deprivation therapy (ADT) after diagnosis of prostate cancer c...

Record $417M award in lawsuit linking baby powder to cancer

This undated photo provided by Robinson Calcagnie, Inc., shows Eva Echevarria. A Los Angeles jury on Monday, Aug. 21, 2017 ordered Johnson & Johnson to pay a record $417 million to Echevarria, a hospitalized woman who claimed in a lawsuit that the talc in the company's iconic baby powder causes ovarian cancer when applied regularly for feminine hygiene.

Combining quantitative and qualitative breast density measures to assess breast cancer risk

Accurately identifying women with dense breasts (Breast Imaging Reporting and Data System [BI-RADS] heterogeneously or extremely dense) who are at high breast cancer risk will facilitate discussions of supplem...

Assessment of the prognostic role of a 94-single nucleotide polymorphisms risk score in early breast cancer in the SIGNAL/PHARE prospective cohort: no correlation with clinico-pathological characteristics and outcomes

Genome-wide association studies (GWAS) have to date identified 94 genetic variants (single nucleotide polymorphisms (SNPs)) associated with risk of developing breast cancer. A score based on the combined effec...

These 3 Biotechs Could Have the Most Exciting Late-Stage Cancer Candidates

  Life Sciences Jobs   ...

Quick Search
Advertisement
 

review and buy Prostate Cancer research and development market research data and corporate reports here